Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX)
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Denosumab (Primary) ; Paclitaxel (Primary) ; Carboplatin; Cyclophosphamide; Epirubicin; Pertuzumab; Trastuzumab
- Indications Breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms GeparX
- 10 Jun 2017 Biomarkers information updated
- 22 Feb 2017 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
- 22 Feb 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.